Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Telegraph Hill Partners is a venture capital firm founded in 2001 and headquartered in San Francisco, California. The firm focuses on providing growth capital to life science, medical device, and healthcare companies, helping them achieve their growth objectives. With a total AUM exceeding $1 billion across multiple funds, including their latest $525 million Fund V, Telegraph Hill Partners has established itself as a significant player in the venture capital landscape.
In addition to its San Francisco headquarters, the firm operates from locations in Research Triangle Park, North Carolina, and has a presence in Miami, Florida, and New Haven, Connecticut. This multi-office structure allows them to tap into diverse markets and opportunities within the healthcare sector. Since its inception, the firm has consistently targeted innovative technologies and strong management teams, positioning itself as a key partner for companies poised for significant impact in their respective fields.
Telegraph Hill Partners invests in private life science and healthcare companies that possess validated technologies, a solid customer base, and innovative management teams. The firm’s investment strategy encompasses growth equity, acquisitions, and management buyouts, often serving as the first institutional investor for boot-strapped companies. Key sectors of focus include healthcare IT, diagnostics, medical devices, and discovery tools and automation.
The firm typically seeks to invest in companies that are at a growth stage, providing not only capital but also strategic guidance to help navigate challenges and seize opportunities. Their check sizes vary, reflecting the specific needs of the companies they partner with, and they emphasize a collaborative approach to support their portfolio companies throughout their lifecycle.
Telegraph Hill Partners has a notable portfolio consisting of six companies, each contributing to advancements in healthcare and life sciences:
These companies exemplify the firm’s commitment to investing in innovative technologies that have the potential to make a significant impact in the healthcare sector.
J. Matthew Mackowski - Chairman, Managing Director. He has extensive experience in venture capital and has led numerous successful investments in the life sciences sector.
Thomas Raffin, M.D. - Venture Partner. Dr. Raffin brings a wealth of medical expertise and has been involved in various healthcare investments.
Deval Lashkari, Ph.D. - Senior Partner. Dr. Lashkari has a strong background in life sciences and has played a key role in the firm’s investment strategy.
Jeanette Welsh, J.D. - Partner, CFO, COO. Welsh oversees financial operations and compliance, ensuring the firm’s fiscal health.
Rob Hart, J.D., CFA - Partner. Hart has a diverse background in finance and law, contributing to the firm’s investment decisions.
Alexander Herzick - Partner. Herzick focuses on identifying and evaluating new investment opportunities in the healthcare sector.
Gary Curtis - Venture Partner. Curtis has significant experience in venture capital and has been involved in multiple successful exits.
Paul Grossman, Ph.D. - Partner. Grossman specializes in life sciences investments and has a strong academic background.
Rob Capone - Partner. Capone has a diverse investment background and contributes to the firm’s strategic direction.
Anna Constantine - Associate. Constantine supports the investment team in evaluating potential opportunities.
Jackson Savage - Associate. Savage assists in research and analysis for investment decisions.
Peter Dansky - Senior Advisor. Dansky provides strategic insights based on his extensive industry experience.
Brett Williams - Senior Advisor. Williams offers guidance on investment strategy and portfolio management.
Robert Shepler - Partner Emeritus. Shepler has a long history with the firm and provides mentorship to the team.
Kate Cilio - Senior Administrative Coordinator. Cilio manages administrative functions and supports the team’s operations.
Linda Gregoire - Accounting and HR Manager. Gregoire oversees financial and human resources operations.
Anthony Manupella - Controller. Manupella manages the firm’s financial reporting and compliance.
To pitch to Telegraph Hill Partners, founders should send an email to info@thpartners.net. A well-structured pitch deck is essential, including details about the business model, market opportunity, and team. The firm values clarity and thoroughness in presentations.
Response times can vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred but not mandatory.
On July 1, 2022, Telegraph Hill Partners closed its fifth fund, raising $525 million to invest in life science and healthcare companies. This fund aims to support innovative businesses with validated technologies and established customer bases.
In 2021, Akoya Biosciences went public and was subsequently acquired by Quanterix in 2025, marking a significant exit for the firm. Additionally, Asuragen was acquired by Bio-Techne in 2021, further demonstrating the firm's successful investment strategy.
What are the investment criteria for Telegraph Hill Partners?
Telegraph Hill Partners focuses on private life science and healthcare companies with validated technologies, a solid customer base, and innovative management teams. They look for businesses that are poised for growth and can benefit from strategic guidance.
How can I apply or pitch to Telegraph Hill Partners?
Founders can reach out via email at info@thpartners.net to initiate a conversation. A well-prepared pitch deck that outlines the business model, market opportunity, and team is essential for consideration.
What makes Telegraph Hill Partners different from other investors?
The firm specializes exclusively in growth equity for life sciences and healthcare sectors, providing not only capital but also strategic guidance and support for growth initiatives, acquisitions, and management buyouts.
What is the geographic scope of their investments?
Telegraph Hill Partners primarily invests in North America, with a strong presence in San Francisco and additional offices in Research Triangle Park, North Carolina, Miami, Florida, and New Haven, Connecticut.
What is the typical check size for investments?
While specific check sizes are not publicly disclosed, the firm typically invests in growth equity rounds, which can vary based on the needs of the portfolio companies.
What kind of post-investment involvement can founders expect?
Telegraph Hill Partners provides ongoing support to its portfolio companies, offering strategic guidance and assistance in navigating challenges, as well as opportunities for follow-on investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.